TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03605888

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Koa Family
Description: Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Koa Family
Description: Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign.
Study: NCT03660423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Dance
Description: Integrative dance may be defined as dance that encourages the participation of all individuals, regardless of ability, supporting and celebrating these differences as a community. In the intervention, adults with developmental disabilities will be dancing in a contemporary dance class alongside college students.
Study: NCT02833077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLUMA® XC
Description: JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM VOLUMA® XC
Description: JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.
Study: NCT01938053

Intervention type: OTHER
Group type: OTHER
Intervention: Call when test results are ready
Description: Patients are called when the test results are ready

Intervention type: OTHER
Group type: OTHER
Intervention: Call when test results are ready
Description: Patients are called when the test results are ready

Intervention type: OTHER
Group type: OTHER
Intervention: Text message when test results are ready
Description: Patients receive a text message when results are ready

Intervention type: OTHER
Group type: OTHER
Intervention: Text message when test results are ready
Description: Patients receive a text message when results are ready

Intervention type: OTHER
Group type: OTHER
Intervention: Call and text message when test results are ready
Description: Patients receive both a call and a text message when test results are resay

Intervention type: OTHER
Group type: OTHER
Intervention: Call and text message when test results are ready
Description: Patients receive both a call and a text message when test results are resay
Study: NCT02826382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]P15-041
Description: Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]P15-041
Description: Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041
Study: NCT03439813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASK-CBT
Description: .Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TASK-Relax
Description: Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
Study: NCT05795803

Intervention type: OTHER
Intervention: Forced isolation context
Description: Exposure to the forced isolation context provided by the ongoing Covid-19 pandemic restrictive measures

Intervention type: OTHER
Intervention: Forced isolation context
Description: Exposure to the forced isolation context provided by the ongoing Covid-19 pandemic restrictive measures
Study: NCT02614547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547
Description: Administered as intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as intravenous infusion.
Study: NCT01878396

Intervention type: DRUG
Intervention: Anti-B-RAF
Study: NCT03455270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T48
Description: oral SERD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T48
Description: oral SERD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T48
Description: oral SERD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T48
Description: oral SERD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4/6 Inhibitor
Study: NCT03807895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REBT Career Intervention
Description: Eight sessions of regular career intervention with rational emotive behavioral therapy (REBT) methods.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Career Intervention
Description: Eight sessions of regular career intervention.
Study: NCT01495598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 5 mg by mouth (p.o.) for 21 of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 5 mg by mouth (p.o.) for 21 of 28 days
Study: NCT03501953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Six weeks of instructor-led physical activity sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Six weeks of instructor-led physical activity sessions.
Study: NCT01981226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracoporeal shock wave
Description: Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
Study: NCT01213524

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensorimotor replacement
Description: denicotinized cigarettes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensorimotor replacement
Description: denicotinized cigarettes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 42 mg transdermal nicotine replacement
Description: 2 21-mg nicotine patches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 42 mg transdermal nicotine replacement
Description: 2 21-mg nicotine patches

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal nicotine
Description: 2 placebo patches matched to 21-mg nicotine patches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo transdermal nicotine
Description: 2 placebo patches matched to 21-mg nicotine patches

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual brand smoking
Description: participant smokes usual brand of cigarette
Study: NCT03695653

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drink Tracking (MA)
Description: Weekly drink tracking for self-monitoring and assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Tailored (TA)
Description: Messages are sent more frequently and tailored to some baseline characteristics and adapt to progress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored (TO)
Description: Messages are sent more frequently and tailored to some baseline characteristics
Study: NCT01836939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSO 2500
Description: TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSO 7500
Description: 12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
Study: NCT03532503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Transcervical foley catheter will be applied

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Transcervical foley catheter will be applied
Study: NCT02944812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
Study: NCT01040169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arginine/Calcium Carbonate
Description: One application

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mint Prophy paste - Fluoride free
Description: one application
Study: NCT00871286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-treatment Sinus CT Scan
Description: Pre-treatment Sinus CT Scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Post-treatment Sinus CT Scan
Description: Post-treatment Sinus CT Scan
Study: NCT04126252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate 50Mg Tab
Description: The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Psychotherapy
Description: The Group B received cognitive behavior psychotherapy for a period of max 3 months.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined or Integrated Therapy
Description: The Group C received the combined therapeutic approach for a period of max 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Group D received no treatment or placebo for a period of max 3 months.
Study: NCT04455503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVX-02A
Description: Up to 8 patients will receive EVX-02A administered IM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVX-02B
Description: Up to 8 patients will receive EVX-02B administered IM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVX-02A OR EVX-02B
Description: EVX-02A or EVX-02B will be used. Patients: 24 to 30
Study: NCT00350727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib is a novel compound being developed for the treatment of various cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib is a novel compound being developed for the treatment of various cancers.
Study: NCT03847649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: 1500 mg IV, 60 min, Day 1 every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: 1500 mg IV, 60 min, Day 1 every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: 1500 mg IV, 60 min, Day 1 every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 0.5mg/kg; PO, Daily cycles 1 \& 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 10mg, PO, Daily cycles 1 \& 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
Study: NCT03850132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAM-SOTC-PL
Description: The adapted FAM-SOTC-PL intervention was delivered at the home of the participants and focuses on supporting the effective, cognitive, and behavioural domains of the bereaved family caregivers experience by targeting concerns/issues in these categories. The FAM-SOTC-PL comprises of the following five components:~1. Drawing forward narratives about the pre- and post-loss experience.~2. Asking therapeutic/interventive questions, emphasising on the most pressing concerns also assessing health issues.~3. Validating/acknowledging emotional responses.~4. Assessing the need for specific information and recommendations regarding bereavement.~5. The use of commendation/commending strengths, by focusing on and affirming the strengths of the family caregiver.
Study: NCT01976572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colestilan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colestilan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colestilan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: candesartan
Study: NCT03318770

Intervention type: DRUG
Intervention: Dasatinib and blinatumomab
Description: Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
Study: NCT03229655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protocol for increasing number of stents across the anastomosis
Description: Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol for increasing number of stents across the anastomosis
Description: Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
Study: NCT03990675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FNA, FNB
Description: Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
Study: NCT05089123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M [Inactivated split influenza vaccine]
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Split Influenza Vaccine
Description: solution for intramuscular injection, 0.5 ml
Study: NCT03029533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: DWJ108J, SC injection, once(Day1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Leuplin DPS Inj, SC injection, once(Day1)
Study: NCT00821210

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: CPAP with pressure of 3cm H2O

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP of optimal pressure
Description: CPAP of optimal pressure
Study: NCT01471444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
Study: NCT04064515

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Assayed for CTCs
Description: All study participants will have 15 mL of blood drawn for the purpose of the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Assayed for CTCs
Description: All study participants will have 15 mL of blood drawn for the purpose of the study.
Study: NCT01976572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: candesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: candesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: candesartan
Study: NCT02600312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oXiris
Description: oXiris CRRT filter which adsorbs cytokines, toxins.
Study: NCT04155203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Calcium
Description: mupirocin cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin Calcium
Description: Reference mupirocin cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: vehicle control cream
Study: NCT04259827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuronation
Description: Online cognitive training app, with exercises created for patients with mild cognitive impairment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aspecific online games
Description: Online gaming without cognitive training
Study: NCT04685837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercise
Description: As soon as the study investigators have obtained a significant sample of patients with non-specific sub-acute low back pain, the intervention will begin.~The principal investigator will perform an individual assessment of the patients. At the end of the assessment, he will randomly distribute them into two groups. Tele-rehabilitation group and face-to-face group.~On the one hand, the main researcher will explain the application works to the tele-rehabilitation group. For 8 weeks, they have to perform 2 therapy exercise training sessions following the instructions on the application.~On the other hand, the researcher will explain the protocol to be followed by the group face to face. In addition, he will provide a schedule to follow a correct development of the protocol. Like the tele-rehabilitation group, they will carry out 16 sessions over 8 weeks.~At the end of the protocol, the principal investigator will perform an individualized assessment of each of the study participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercise
Description: As soon as the study investigators have obtained a significant sample of patients with non-specific sub-acute low back pain, the intervention will begin.~The principal investigator will perform an individual assessment of the patients. At the end of the assessment, he will randomly distribute them into two groups. Tele-rehabilitation group and face-to-face group.~On the one hand, the main researcher will explain the application works to the tele-rehabilitation group. For 8 weeks, they have to perform 2 therapy exercise training sessions following the instructions on the application.~On the other hand, the researcher will explain the protocol to be followed by the group face to face. In addition, he will provide a schedule to follow a correct development of the protocol. Like the tele-rehabilitation group, they will carry out 16 sessions over 8 weeks.~At the end of the protocol, the principal investigator will perform an individualized assessment of each of the study participants.
Study: NCT03812042

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme assay and molecular sequencing
Description: Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
Study: NCT01853267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Group (Non-Packing)
Description: The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group (Packing)
Description: After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
Study: NCT00555529

Intervention type: PROCEDURE
Intervention: radial artery applanation tonometry (RAAP)
Description: non-invasive tonometry

Intervention type: PROCEDURE
Intervention: radial artery applanation tonometry (RAAP)
Description: non-invasive tonometry
Study: NCT03548220

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching AG-348 tablets, administered to maintain the blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: AG-348 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: AG-348 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: AG-348 tablets.
Study: NCT02049853

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTproBNP measurement with point of care device Cobash232 in the POCT group
Study: NCT01619072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol + referral
Description: 800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + referral
Description: Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
Study: NCT04198909

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocochleography, electrophysiology thet for analyse the wave I generated by the auditory pathways
Description: Electrocochleography is a technique that analyses the functionality of inner ear.
Study: NCT04469634

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessing antibody responses, neutralizing capacity and memory B-cell function
Description: Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection
Study: NCT00501657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg mane for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg mane for 2 days